Literature DB >> 8833444

Gene transfer to neurons using herpes simplex virus-based vectors.

D J Fink1, N A DeLuca, W F Goins, J C Glorioso.   

Abstract

One important outgrowth of molecular medicine is the development of technologies for the transfer of therapeutic genes to cells in culture and tissues in vivo, which promises to revolutionize both experimental biomedical science and the clinical practice of medicine. Fundamental obstacles must still be overcome to create safe and efficient gene delivery vectors specifically designed for individual tissue types, and special strategies will be required for direct in vivo gene transfer to neurons because these cells are postmitotic and cannot be removed for transduction. Herpes simplex virus type 1 (HSV-1), a neurotropic virus that naturally establishes a latent state in neurons, has many unique features that make it suitable as a gene transfer vector for the nervous system. In this review we describe the molecular biology of HSV-1, strategies for reducing potential pathogenesis of the recombinant vector, and methods for expressing transgenes from the vector genome. Gene transfer experiments using recombinant HSV-1-based vectors and defective HSV-1 vectors (amplicons) for gene transfer are also described and evaluated in terms of efficiency and safety.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8833444     DOI: 10.1146/annurev.ne.19.030196.001405

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  42 in total

1.  Herpes simplex virus triggers and then disarms a host antiviral response.

Authors:  K L Mossman; P F Macgregor; J J Rozmus; A B Goryachev; A M Edwards; J R Smiley
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 3.  Herpes simplex virus vectors for gene therapy in Parkinson's disease and other diseases of the nervous system.

Authors:  D S Latchman
Journal:  J R Soc Med       Date:  1999-11       Impact factor: 5.344

4.  Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system.

Authors:  J A Palmer; R H Branston; C E Lilley; M J Robinson; F Groutsi; J Smith; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Efficiency of expression of transfected genes depends on the cell cycle.

Authors:  S Marenzi; R L Adams; G Zardo; L Lenti; A Reale; P Caiafa
Journal:  Mol Biol Rep       Date:  1999-12       Impact factor: 2.316

6.  Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture.

Authors:  X p Chen; J Li; M Mata; J Goss; D Wolfe; J C Glorioso; D J Fink
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 7.  Gene therapy: novel treatments for polyneuropathy and chronic pain.

Authors:  Marina Mata; Joseph C Glorioso; David J Fink
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

8.  Use of Adeno-Associated and Herpes Simplex Viral Vectors for In Vivo Neuronal Expression in Mice.

Authors:  Rachel D Penrod; Audrey M Wells; William A Carlezon; Christopher W Cowan
Journal:  Curr Protoc Neurosci       Date:  2015-10-01

9.  Increasing CRTC1 function in the dentate gyrus during memory formation or reactivation increases memory strength without compromising memory quality.

Authors:  Melanie J Sekeres; Valentina Mercaldo; Blake Richards; Derya Sargin; Vivek Mahadevan; Melanie A Woodin; Paul W Frankland; Sheena A Josselyn
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

Review 10.  Gene therapy for the treatment of diabetic neuropathy.

Authors:  Marina Mata; Munmun Chattopadhyay; David J Fink
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.